What is ITP

ITP and You 

Immune thrombocytopenia (ITP)

Only nine or ten people in every 100,000 have ITP, a rare autoimmune disease affecting platelet production and characterised by fatigue, bruising and bleeding. Until recently, ITP management has tended to be ruled by compromise. But now, thanks to increased treatment options and disease awareness, improved quality of life may be possible for people living with ITP. 1,2,3

 ITP stands for immune thrombocytopenia. The disease was previously known as idiopathic thrombocytopenic purpura, and this term may still be used. If the condition persists for more than a year, it is called chronic immune thrombocytopenia.

my-ITP.com is designed to navigate through ITP. This website contains information on ITP symptoms, diagnosis, living with ITP and useful tips and advice to help you navigate everyday life or support somebody with this ITP rare condition. 

Patient organisations and support groups

Patient Organisations and Support Groups offer a wealth of information and advice that you may find useful and they may be able to connect you with other people who are also living with ITP.

For more information about Patient Organisations and Patient Support Groups in your country, please refer to ITP in Adults.

For medical advice please contact your doctor. 

For more information and support on managing your ITP from a holistic approach, Platelet Disorder Support Association - Empowering ITP Patients - Home (pdsa.org) offers, among other resources, a range of different materials on yoga, nutrition, fitness and mindfulness.

References

https://rarediseases.org/rare-diseases/immune-thrombocytopenia/

2 Immune Thrombocytopenia (ITP): Current Limitations in Patient Management. Terrell DR, Neunert CE, Cooper N, Heitink-Pollé KM, Kruse C, Imbach P, Kühne T, Ghanima W. Medicina (Kaunas). 2020 Nov 30;56(12):667. doi: 10.3390/medicina56120667. PMID: 33266286

3 Epidemiology and Clinical Manifestations of Immune ThrombocytopeniaRahil Kohli, Shruti Chaturvedi. Hamostaseologie 2019; 39(03): 238-249